Funding Archives

News and Trends 16 Mar 2023

Mediar Therapeutics boosts fibrosis portfolio with $105M financing

Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, has announced a $105 million financing. This includes a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol […]

March 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 15 Mar 2023

Nanite receives funding to deliver genetic therapies to the lungs

Nanite Inc. has announced an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung. This builds on the $6 million seed financing recently announced by the company. One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug […]

March 15, 2023 - 2 minutesmins - By Jim Cornall

artificial intelligence AI drug discovery

News and Trends 9 Mar 2023

Iktos raises €15.5M to expand AI drug discovery technologies

Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […]

March 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Mar 2023

Ampersand Biomedicines launched to develop drugs that only work at disease sites

Flagship Pioneering has created Ampersand Biomedicines, a company creating programmable medicines that are intended to be safer, more tolerable, and effective by acting at the site of disease. Flagship Pioneering has initially committed $50 million to advance the company’s Address, Navigate, Design (AND) platform and develop an initial pipeline of medicines across a range of […]

March 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

Noema Pharma raises $112 million in Series B financing

Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor […]

March 8, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Genomic medicine company Chroma raises $135M

Chroma Medicine, Inc., a genomic medicine company advancing single-dose epigenetic editing therapeutics, has completed a $135 million Series B financing. The funding was led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, […]

March 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Ten new companies join BioInnovation Institute’s Venture Lab program

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating life science research, has added 10 new companies to its Venture Lab acceleration program for early-stage companies. The cohort is aligned with BioInnovation Institute’s focus on supporting innovative early-stage start-ups within human and planetary health. The 12-month program is designed to support start-up companies with […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

Opinion 28 Feb 2023

Life changing treatments for rare disease – a beacon of hope

By Sander Slootweg, managing partner, Forbion More than 300 million people around the globe are affected by a rare disease. This number does not even take into account the impact on these individuals’ support units that includes family, friends and caregivers. A rare disease is defined as a disease that affects no more than 1 […]

February 28, 2023 - 6 minutesmins - By External Contributor

News and Trends 24 Feb 2023

Resalis Therapeutics receives €10M to develop obesity and NAFLD treatment

Resalis Therapeutics has completed a seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases. The funding will support the finalization of IND-enabling studies for the Resalis Therapeutics’ lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty […]

February 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Italian life sciences fund hits €175M

Panakès Partners, an Italian venture capital firm in the life sciences sector, has closed its Purple Fund with a total of €175 million ($185.4 million). Panakès Purple Fund is currently the largest Italian Venture Capital Fund, in the investment phase, dedicated to life sciences, with an investment focus in Italy and Europe, as well as […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders

Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has announced the closing of an oversubscribed $135 million Series B financing. Access Biotechnology led the round, with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well […]

February 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Avilar Therapeutics financing up to $75M to boost extracellular protein degraders pipeline

Avilar Therapeutics has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders. The new financing takes the company’s total to $75 million. The seed round had initial funding from Avilar’s founding investor, RA Capital Management, and now includes participation by new investors Sanofi Ventures, […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us